Product Information
FROVATRIPTAN SUCC 2.5 MG TAB is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $2.7171 per EA under NDC 68462069497. Its NADAC has been published 537 times since Jun 22, 2016.
FDA first approved this application on Mar 11, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462069497
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FROVATRIPTAN SUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA204730FDA Approved
3/11/2016
TE Code
AB
On Market Since
3/11/2016
Pharmacological Classes
Price Statistics
The NADAC for FROVATRIPTAN SUCC 2.5 MG TAB has been published 537 times since Jun 22, 2016, and over the history we have for it it has declined 92.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.7171 per EA |
|---|---|
| All-time high | $50.9833 (Oct 12, 2016) |
| All-time low | $2.7171 (Sep 23, 2026) |
| 52-week high | $3.6263 |
| 52-week low | $2.7171 |
| Median price | $17.3014 |
| Average price | $18.8662 |
| Largest weekly change | +77.7% (Jun 19, 2024) |
| Weeks tracked | 537 |
| Tracking since | Jun 22, 2016 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
frovatriptan succinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FROVATRIPTAN SUCC 2.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for FROVATRIPTAN SUCC 2.5 MG TAB, manufactured by Glenmark Pharmaceuticals Inc., USA, is $2.7171 per EA (NDC 68462069497), effective Sep 30, 2026.
How has the price of FROVATRIPTAN SUCC 2.5 MG TAB changed over time?
Over the history we have for it, the NADAC for FROVATRIPTAN SUCC 2.5 MG TAB has declined 92.3%. It has been tracked across 537 weekly CMS publications since Jun 22, 2016.
What are the highest and lowest recorded NADAC prices for FROVATRIPTAN SUCC 2.5 MG TAB?
Since Jun 22, 2016, the NADAC for FROVATRIPTAN SUCC 2.5 MG TAB has ranged from a low of $2.7171 (Sep 23, 2026) to a high of $50.9833 (Oct 12, 2016), with a median of $17.3014 per EA.
Are there cheaper alternatives to FROVATRIPTAN SUCC 2.5 MG TAB?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FROVATRIPTAN SUCC 2.5 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures FROVATRIPTAN SUCC 2.5 MG TAB?
FROVATRIPTAN SUCC 2.5 MG TAB (NDC 68462069497) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.